Pradefovir, a liver-targeted prodrug of adefovir against HBV infection.
Metabasis Therapeutics Inc (previously Ribapharm Inc) is developing pradefovir, an oral liver-targeting prodrug of adefovir developed using its HepDirect technology, for the potential treatment of HBV infection. Phase II clinical trials of pradefovir have been completed.
University of Leipzig, Philipp-Rosenthal Street 27, Leipzig 04103, Germany. hans.tillmann@medizin.uni-leipzig.de
Hans L
HL
Tillmann
D000225:Adenine / Q000031:analogs & derivatives* / Q000138:chemical synthesis / Q000493:pharmacokinetics / Q000627:therapeutic use; D000998:Antiviral Agents / Q000138:chemical synthesis / Q000493:pharmacokinetics / Q000627:therapeutic use; D017321:Clinical Trials, Phase I as Topic; D017322:Clinical Trials, Phase II as Topic; D016503:Drug Delivery Systems; D019694:Hepatitis B, Chronic / Q000188:drug therapy*; D006801:Humans; D008099:Liver / Q000378:metabolism*; D063065:Organophosphonates / Q000493:pharmacokinetics / Q000627:therapeutic use; D009943:Organophosphorus Compounds / Q000138:chemical synthesis / Q000493:pharmacokinetics / Q000627:therapeutic use; D011355:Prodrugs / Q000138:chemical synthesis / Q000493:pharmacokinetics / Q000627:therapeutic use; D013329:Structure-Activity Relationship
D000998:Antiviral Agents; D063065:Organophosphonates; D009943:Organophosphorus Compounds; D011355:Prodrugs; C053001:adefovir; C497721:pradefovir; D000225:Adenine